Clinical trial
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With…
NCT00152451 · UCB S.A. - Pharma Sector, Industry · Completed
Key facts
| NCT number | NCT00152451 |
|---|---|
| Title | Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures |
| Official title | An Open-label, Exploratory, Multicenter, Dose-escalation Study Examining the Efficacy, Safety and Tolerability of Ucb 44212 Used at Doses of 10 mg, 20 mg, 40 mg and 80 mg b.i.d. (Total Daily Dose of 20 to 160 mg) in Adult Subjects (18-65 Years) With Refractory Epilepsy Suffering From Partial Onset… |
| Lead sponsor | UCB S.A. - Pharma Sector, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epilepsy, Partial |
| Intervention type | Drug |
| Interventions | Seletracetam (ucb 44212) |
| Enrollment | 31 |
| Start date | May 19, 2005 |
| Primary completion | May 3, 2006 |
| Completion | May 3, 2006 |
| First posted | Sep 9, 2005 |
| Last update posted | Mar 29, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: